Related Experiment Videos
Desmopressin in nocturnal enuresis
Archives of Disease in Childhood
|February 1, 1982
Summary
Desamino-D-arginine vasopressin (DDAVP) significantly reduced bedwetting in children. The treatment was most effective in children over 10 years old and showed no adverse effects.
Area of Science:
- Pediatrics
- Pharmacology
Background:
- Nocturnal enuresis, or bedwetting, affects many children.
- Desamino-D-arginine vasopressin (DDAVP) is a synthetic analog of vasopressin.
Purpose of the Study:
- To evaluate the efficacy and safety of DDAVP in treating nocturnal enuresis in children.
- To determine if DDAVP's effectiveness varies with age.
Main Methods:
- A double-blind clinical study was conducted on 32 children with enuresis.
- Children received either DDAVP or a placebo (details of placebo group not provided in abstract).
- Data collected included frequency of wet nights and urine osmolality.
Main Results:
- DDAVP treatment significantly reduced wet nights from 18.7 to 6.5 per 30 days.
- Complete cessation of bedwetting occurred in 6 children, with satisfactory response in another 6.
- Older children (over 10 years) showed a significantly better response to DDAVP.
Conclusions:
- DDAVP is an effective treatment for nocturnal enuresis, especially in older children.
- The positive effects of DDAVP may involve mechanisms beyond its antidiuretic properties.
- No adverse effects were observed during the study.